Pharmacogenomics of Thiopurine S-Methyltransferase: Clinical Applicability of Genetic Variants

Pavlović, Sonja; Zukić, Branka; Nikčević, Gordana

doi:10.5772/26588

Cited by 3 publications

(2 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Giving the state of the art of pharmacogenomic testing, Pavlovic highlighted that there is an immense number of candidates for pharmacogenomic testing [ 7 ] and that professionals could be confused what genetic variations should be taken into account. Therefore, Pavlovic identified obligatory and recommended pharmacogenomic markers (approved by FDA, EMA, and PMDA) [ 8 , 9 ]. The most relevant pharmacogenomic tests are routinely performed in Serbian accredited laboratories.…”

Section: The 6th Golden Helix Pharmacogenomics Daymentioning

confidence: 99%

6th Golden Helix Pharmacogenomics Day: pharmacogenomics and individualized therapy

Stojiljković

Fazlagić²,

Dokmanovic-Krivokapic

et al. 2012

Hum Genomics

Self Cite

View full text Add to dashboard Cite

The Golden Helix Pharmacogenomics Days are international scientific meetings aiming to educate healthcare professionals and biomedical scientists about pharmacogenomics and personalized medicine. In this meeting report, we provide an overview of the scientific lectures and the topics discussed during the 6th Golden Helix Pharmacogenomics Day that was held in Belgrade, Serbia last June 5, 2012. The scientific program included lectures by the local and international speakers from Europe and the United States.

show abstract

Section: The 6th Golden Helix Pharmacogenomics Daymentioning

confidence: 99%

6th Golden Helix Pharmacogenomics Day: pharmacogenomics and individualized therapy

Stojiljković

Fazlagić²,

Dokmanovic-Krivokapic

et al. 2012

Hum Genomics

Self Cite

View full text Add to dashboard Cite

show abstract

“…For some medications pharmacogenomic testing is just recommended, but for the majority of drugs, the testing used today is only informative (41). Introducing routine pharmacogenomic testing into clinical practice enables patients to get an adequate therapy (correct medications and correct drug dose) in accordance with their genotype (42). This approach reduces duration of treat ment, saves the health care system a lot of money for unnecessary medications and provides minimal complications and adverse reactions to the drug.…”

Section: Pharmacogenetics and Pharmacogenomicsmentioning

confidence: 99%

Molecular Genetic Markers as a Basis for Personalized Medicine / MOLEKULARNO-GENETIČKI MARKERI KAO OSNOV ZA PERSONALIZOVANU MEDICINU

Pavlović¹,

Zukić²,

Petrović³

2014

Journal of Medical Biochemistry

View full text Add to dashboard Cite

Summary Nowadays, genetics and genomics are fully integrated into medical practice. Personalized medicine, also called genome-based medicine, uses the knowledge of the genetic basis of disease to individualize treatment for each patient. A number of genetic variants, molecular genetic markers, are already in use in medical practice for the diagnosis, prognosis and follow-up of diseases (monogenic hereditary disorders, fusion genes and rearrangements in pediatric and adult leukemia) and presymptomatic risk assessment (BRCA 1/2 for breast cancer). Additionally, the application of pharmacogenomics in clinical practice has significantly contributed to the individualization of therapy in accordance with the patient’s genotype and gene expression profile. Genetic testing for several pharmacogenomic markers (TPMT, UGT1A1, CYP2C9, VKORC1) is mandatory or recommended prior to the initiation of therapy. The most important achievement of genome-based medicine is molecular-targeted therapy, tailored to the genetic profile of a disease. Testing for gene variants in cancer (BCR-ABL, PML/RARa, RAS, BCL-2) is part of the recommended evaluation for different cancers, in order to achieve better management of the disease. The ultimate goal of medical science is to develop gene therapy which will fight or prevent a disease by targeting the disease causing genetic defect. Gene therapy technology is rapidly developing, and has already been used with success. Although medicine has always been essentially »personal« to each patient, personalized medicine today uses modern technology and knowledge in the field of molecular genetics and genomics, enabling a level of personalization which leads to significant improvement in health care.

show abstract

Genetic variation in key genes associated with statin therapy in the Azores Islands (Portugal) healthy population

Melo

Balanco

Branco³

et al. 2014

Annals of Human Biology

View full text Add to dashboard Cite

The results contribute to overcome the lack of knowledge regarding the frequency of pharmacogenetic SNPs and their corresponding haplotypes in targeted populations, such as Azores islands. Moreover, the present work constitutes an initial step to implementing pharmacogenomics in clinical practice where physicians could use a patient's genetic make-up to optimize statin therapy, regarding efficiency and myopathy risk.

show abstract

Pharmacogenomics of Thiopurine S-Methyltransferase: Clinical Applicability of Genetic Variants

Cited by 3 publications

References 94 publications

6th Golden Helix Pharmacogenomics Day: pharmacogenomics and individualized therapy

6th Golden Helix Pharmacogenomics Day: pharmacogenomics and individualized therapy

Molecular Genetic Markers as a Basis for Personalized Medicine / MOLEKULARNO-GENETIČKI MARKERI KAO OSNOV ZA PERSONALIZOVANU MEDICINU

Genetic variation in key genes associated with statin therapy in the Azores Islands (Portugal) healthy population

Contact Info

Product

Resources

About